PT2989084T - Modificações cristalinas de elobixibat - Google Patents

Modificações cristalinas de elobixibat

Info

Publication number: PT2989084T
Authority: PT; Portugal
Prior art keywords: elobixibat; crystal modifications; crystal; modifications
Prior art date: 2013-04-26

Application number

PT147193312T

Other languages

English (en)

Inventor

Bohlin Martin

Tjerneld Erica

Vestermark Andreas

Ymén Ingvar

Original Assignee

Elobix Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-04-26

Filing date

2014-04-25

Publication date

2017-04-24

2014-04-25 Application filed by Elobix Ab filed Critical Elobix Ab

2017-04-24 Publication of PT2989084T publication Critical patent/PT2989084T/pt

Links

239000013078 crystal Substances 0.000 title 1
XFLQIRAKKLNXRQ-UUWRZZSWSA-N elobixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C=3C=CC=CC=3)C=C2S(=O)(=O)CC(CCCC)(CCCC)CN1C1=CC=CC=C1 XFLQIRAKKLNXRQ-UUWRZZSWSA-N 0.000 title 1
229950000820 elobixibat Drugs 0.000 title 1
108010007192 elobixibat Proteins 0.000 title 1
238000012986 modification Methods 0.000 title 1
230000004048 modification Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Dermatology (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Electroluminescent Light Sources (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

PT147193312T 2013-04-26 2014-04-25 Modificações cristalinas de elobixibat PT2989084T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE1350517		2013-04-26

Publications (1)

Publication Number	Publication Date
PT2989084T true PT2989084T (pt)	2017-04-24

Family

ID=50549341

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT147193312T PT2989084T (pt)	2013-04-26	2014-04-25	Modificações cristalinas de elobixibat

Country Status (27)

Country	Link
US (3)	US9409875B2 (pt)
EP (1)	EP2989084B1 (pt)
JP (1)	JP6456921B2 (pt)
KR (3)	KR20210148400A (pt)
CN (2)	CN105143194B (pt)
AR (1)	AR096115A1 (pt)
AU (1)	AU2014259433B2 (pt)
BR (1)	BR112015026711A2 (pt)
CA (1)	CA2907842C (pt)
CL (1)	CL2015003117A1 (pt)
DK (1)	DK2989084T3 (pt)
ES (1)	ES2622181T3 (pt)
IL (1)	IL241766B (pt)
JO (1)	JO3301B1 (pt)
MX (1)	MX370299B (pt)
MY (1)	MY176157A (pt)
NZ (1)	NZ713281A (pt)
PH (2)	PH12015502309B1 (pt)
PL (1)	PL2989084T3 (pt)
PT (1)	PT2989084T (pt)
RU (1)	RU2666368C2 (pt)
SA (1)	SA515361232B1 (pt)
SG (1)	SG11201507717SA (pt)
TW (1)	TWI624261B (pt)
UA (1)	UA118847C2 (pt)
WO (1)	WO2014174066A1 (pt)
ZA (1)	ZA201507110B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2586931T3 (es)	2010-11-04	2016-10-19	Albireo Ab	Inhibidores de IBAT para el tratamiento de enfermedades hepáticas
JO3301B1 (ar) *	2013-04-26	2018-09-16	Albireo Ab	تعديلات بلورية على إيلوبيكسيبات
CN106659726A (zh)	2014-06-25	2017-05-10	Ea制药株式会社	固体制剂及其着色防止或着色减少方法
EP3012252A1 (en) *	2014-10-24	2016-04-27	Ferring BV	Crystal modifications of elobixibat
EP3413875B1 (en)	2016-02-09	2020-01-29	Albireo AB	Cholestyramine pellets and methods for preparation thereof
EP3413878B1 (en)	2016-02-09	2021-04-14	Albireo AB	Oral cholestyramine formulation and use thereof
EP3413877B1 (en)	2016-02-09	2021-04-07	Albireo AB	Oral cholestyramine formulation and use thereof
JP2020530448A (ja)	2017-08-09	2020-10-22	アルビレオ・アクチボラグ	コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
MX2020009332A (es) *	2018-03-09	2020-10-08	Elobix Ab	Proceso para la preparacion de elobixibat.
JP7391048B2 (ja)	2018-06-05	2023-12-04	アルビレオ・アクチボラグ	ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11801226B2 (en)	2018-06-20	2023-10-31	Albireo Ab	Pharmaceutical formulation of odevixibat
MX2020013839A (es)	2018-06-20	2021-03-25	Albireo Ab	Formulacion farmaceutica de odevixibat.
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
TWI835997B (zh)	2019-02-06	2024-03-21	瑞典商艾爾比瑞歐公司	苯并噻氮呯化合物及其用作膽酸調節劑之用途
RS63899B1 (sr)	2019-02-06	2023-02-28	Albireo Ab	Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina
WO2021049311A1 (ja)	2019-09-09	2021-03-18	エロビクス・アーベー	１，５－ベンゾチアゼピン化合物を製造するための方法
JP7665620B2 (ja)	2019-12-04	2025-04-21	アルビレオ・アクチボラグ	ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3158181A1 (en)	2019-12-04	2021-06-10	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en)	2020-12-04	2021-05-25	Albireo Ab	Benzothiazepine compounds and their use as bile acid modulators
BR112022010505A2 (pt)	2019-12-04	2022-09-06	Albireo Ab	Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
EP4069359B1 (en)	2019-12-04	2024-01-03	Albireo AB	Benzothia(di)azepine compounds and their use as bile acid modulators
CA3186857A1 (en)	2020-08-03	2022-02-10	Per-Goran Gillberg	Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en)	2020-11-12	2023-06-08	Albireo Ab	Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
WO2022101379A1 (en)	2020-11-12	2022-05-19	Albireo Ab	Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en)	2020-12-04	2023-06-22	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh)	2021-06-03	2023-04-01	瑞典商艾爾比瑞歐公司	苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
TW202333724A (zh) *	2021-11-05	2023-09-01	美商米魯姆製藥公司	以迴腸膽酸轉運蛋白(ibat)抑制劑治療以增加無事件存活期(efs)
CN117980295A (zh) *	2022-08-02	2024-05-03	上海皓元医药股份有限公司	一种依洛西巴特晶型ii及其制备方法
CN120379676A (zh)	2022-11-03	2025-07-25	阿尔比里奥公司	治疗阿拉杰里综合征(algs)
AU2024369988A1 (en)	2023-11-03	2026-04-09	Albireo Ab	Treating pfic2 with odevixibat

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3066728D1 (en)	1979-04-30	1984-03-29	Max Planck Gesellschaft	Tyrosine derivatives, process for their production and their use in the synthesis of peptides
US4900757A (en)	1988-12-08	1990-02-13	Merrell Dow Pharmaceuticals Inc.	Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
NZ240846A (en)	1990-12-06	1994-04-27	Hoechst Ag	Dimeric bile acid derivatives; preparatory processes and pharmaceutical compositions
AU653658B2 (en)	1991-12-20	1994-10-06	Hoechst Aktiengesellschaft	Polymers and oligomers of bile acid derivatives, process for their preparation and their use as pharmaceuticals
JPH05186357A (ja)	1991-12-31	1993-07-27	Shigeo Ochi	飲食物消化分解産物吸収抑制手段
GB9203347D0 (en)	1992-02-17	1992-04-01	Wellcome Found	Hypolipidaemic compounds
IT1257793B (it)	1992-05-18	1996-02-13		Composizione farmaceutica a base di acidi biliari in microgranuli a rilascio controllato
DK0573848T3 (da)	1992-06-12	1998-08-10	Hoechst Ag	Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
IL108633A (en)	1993-02-15	1998-07-15	Wellcome Found	History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en)	1993-02-15	1994-05-30	Wellcome Found	Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
TW289757B (pt)	1993-05-08	1996-11-01	Hoechst Ag
EP0624593A3 (de)	1993-05-08	1995-06-07	Hoechst Ag	Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
TW289021B (pt)	1993-05-08	1996-10-21	Hoechst Ag
TW289020B (pt)	1993-05-08	1996-10-21	Hoechst Sktiengesellschaft
ZA956647B (en)	1994-08-10	1997-02-10	Wellcome Found	Hypolipidaemic compounds.
BR9508916A (pt)	1994-09-13	1997-12-30	Monsanto Co	"Novas benzotiepinas tendo atividade como inibidores de transporte do ácido biliar ileal e absorção de taurocolato"
US6262277B1 (en)	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5994391A (en)	1994-09-13	1999-11-30	G.D. Searle And Company	Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
GB9423172D0 (en)	1994-11-17	1995-01-04	Wellcom Foundation The Limited	Hypolipidemic benzothiazepines
US5811388A (en)	1995-06-07	1998-09-22	Cibus Pharmaceutical, Inc.	Delivery of drugs to the lower GI tract
US6069167A (en)	1996-01-16	2000-05-30	University Technology Corporation	Use of antioxidant agents to treat cholestatic liver disease
NZ331813A (en)	1996-03-11	2001-03-30	G	Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake
AU3940897A (en)	1996-07-24	1998-02-10	Zumtobel Staff Gmbh	Adapter for a retaining means used to secure a built-in lamp in a mounting hole,or retaining means or built-in lamp provided with such an adapter
DE19633268A1 (de)	1996-08-19	1998-02-26	Hoechst Ag	Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung
GB9704208D0 (en)	1997-02-28	1997-04-16	Glaxo Group Ltd	Chemical compounds
NZ337830A (en)	1997-03-11	2001-07-27	G	Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
DK0864582T3 (da)	1997-03-14	2003-09-29	Aventis Pharma Gmbh	Hypolidemiske 1,4-benzothiazepin-1,1-dioxider
AUPO763197A0 (en)	1997-06-30	1997-07-24	Sigma Pharmaceuticals Pty Ltd	Health supplement
KR20010015884A (ko)	1997-12-19	2001-02-26	윌리암스 로저 에이	거울상이성질체적으로 풍부한 테트라히드로벤조티에핀옥시드의 제조방법
GB9800428D0 (en)	1998-01-10	1998-03-04	Glaxo Group Ltd	Chemical compounds
US6346527B1 (en)	1998-04-24	2002-02-12	Fujisawa Pharmaceutical Co., Ltd.	Guanidine derivatives
DE19825804C2 (de)	1998-06-10	2000-08-24	Aventis Pharma Gmbh	1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6221897B1 (en)	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
AU5194999A (en)	1998-08-07	2000-02-28	Takeda Chemical Industries Ltd.	Benzothiepin derivatives, process for the preparation of the same and uses thereof
PT1140190E (pt)	1998-12-23	2003-02-28	Searle Llc	Combinacoes de inibidores do transporte ileal dos acidos biliares e agentes sequestrantes dos acidos biliares usadas para problemas cardiovasculares
CN1342091A (zh)	1998-12-23	2002-03-27	G.D.瑟尔有限公司	心血管指征的联合用药
EP1342475A1 (en)	1998-12-23	2003-09-10	G.D. Searle LLC.	Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
KR20010102963A (ko)	1998-12-23	2001-11-17	윌리암스 로저 에이	심장 혈관 징후를 위한 회장 담즙산 수송 저해제와니코틴산 유도체의 조합물
MXPA01006472A (es)	1998-12-23	2004-03-10	Searle Llc	Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares.
CA2362147A1 (en)	1999-02-12	2000-08-17	Steve A. Kolodziej	1,2-benzothiazepines for the treatment of hyperlipidemic diseases
DE19916108C1 (de)	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
SE9901387D0 (sv)	1999-04-19	1999-04-19	Astra Ab	New pharmaceutical foromaulations
US6287609B1 (en)	1999-06-09	2001-09-11	Wisconsin Alumni Research Foundation	Unfermented gel fraction from psyllium seed husks
EP1259494A4 (en)	2000-02-18	2004-09-15	Merck & Co Inc	ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID DISORDERS
SE0000772D0 (sv)	2000-03-08	2000-03-08	Astrazeneca Ab	Chemical compounds
WO2001068096A2 (en)	2000-03-10	2001-09-20	Pharmacia Corporation	Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
EP1286984A2 (en)	2000-03-10	2003-03-05	Pharmacia Corporation	Method for the preparation of tetrahydrobenzothiepines
US20020183307A1 (en)	2000-07-26	2002-12-05	Tremont Samuel J.	Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
FR2812886B1 (fr)	2000-08-08	2002-11-08	Assist Publ Hopitaux De Paris	Depistage d'un nouveau syndrome hepatique et ses applications
SE0003766D0 (sv)	2000-10-18	2000-10-18	Astrazeneca Ab	Novel formulation
EG26979A (en) *	2000-12-21	2015-03-01	Astrazeneca Ab	Chemical compounds
WO2002053548A1 (fr)	2000-12-27	2002-07-11	Banyu Pharmaceutical Co.,Ltd.	Derives de la benzothiazepine
US6506921B1 (en)	2001-06-29	2003-01-14	Virginia Tech Intellectual Properties, Inc.	Amine compounds and curable compositions derived therefrom
GB0121337D0 (en) *	2001-09-04	2001-10-24	Astrazeneca Ab	Chemical compounds
GB0121622D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
GB0121621D0 (en)	2001-09-07	2001-10-31	Astrazeneca Ab	Chemical compounds
PL216023B1 (pl)	2001-09-08	2014-02-28	Astrazeneca Ab	Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny
BR0212495A (pt)	2001-09-12	2004-08-24	Searle Llc	Método para a preparação de tetraidrobenzotiepinas cristalinas
SE0104334D0 (sv)	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
GB0314079D0 (en)	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
GB0229931D0 (en)	2002-12-21	2003-01-29	Astrazeneca Ab	Therapeutic agents
AU2002351752A1 (en)	2001-12-29	2003-07-30	Novo Nordisk A/S	Combined use of a glp-1 compound and another drug for treating dyslipidemia
GB0201850D0 (en)	2002-01-26	2002-03-13	Astrazeneca Ab	Therapeutic treatment
GB0209467D0 (en)	2002-04-25	2002-06-05	Astrazeneca Ab	Chemical compounds
GB0213669D0 (en) *	2002-06-14	2002-07-24	Astrazeneca Ab	Chemical compounds
GB0216321D0 (en)	2002-07-13	2002-08-21	Astrazeneca Ab	Therapeutic treatment
US7312208B2 (en)	2002-08-28	2007-12-25	Asahi Kasei Pharma Corporation	Quaternary ammonium compounds
CN100494185C (zh)	2002-08-28	2009-06-03	旭化成制药株式会社	新型季铵化合物
GB0304194D0 (en)	2003-02-25	2003-03-26	Astrazeneca Ab	Chemical compounds
GB0307918D0 (en)	2003-04-05	2003-05-14	Astrazeneca Ab	Therapeutic use
KR20070026392A (ko)	2004-02-27	2007-03-08	아사히 가세이 파마 가부시키가이샤	신규 벤조티아제핀 및 벤조티에핀 화합물
US20050197376A1 (en)	2004-03-02	2005-09-08	Fujisawa Pharmaceutical Co. Ltd.	Concomitant drugs
EP1593671A1 (en)	2004-03-05	2005-11-09	Graffinity Pharmaceuticals AG	DPP-IV inhibitors
WO2006121861A2 (en)	2005-05-05	2006-11-16	Microbia, Inc.	Biphenylazetidinone cholesterol absorption inhibitors
WO2007004957A1 (en) *	2005-07-05	2007-01-11	Astrazeneca Ab	Novel crystalline form
DE102005033099A1 (de)	2005-07-15	2007-01-18	Sanofi-Aventis Deutschland Gmbh	Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung
DE102005033100B3 (de)	2005-07-15	2007-01-25	Sanofi-Aventis Deutschland Gmbh	Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
KR101368525B1 (ko)	2005-09-20	2014-03-06	노파르티스 아게	저혈당 증상을 저하시키기 위한 ｄｐｐ-ⅳ 억제제의 용도
EP2007395A1 (en) *	2006-04-10	2008-12-31	Merck & Co., Inc.	Cgrp antagonist salt
DE102006053637B4 (de)	2006-11-14	2011-06-30	Sanofi-Aventis Deutschland GmbH, 65929	Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102006053635B4 (de)	2006-11-14	2011-06-30	Sanofi-Aventis Deutschland GmbH, 65929	Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2008058631A1 (de)	2006-11-14	2008-05-22	Sanofi-Aventis Deutschland Gmbh	Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2367554A4 (en)	2008-11-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	Bile acid reflux inhibitor for the treatment of obesity and diabetes
JO3131B1 (ar)	2010-04-27	2017-09-20	Glaxosmithkline Llc	مركبات كيميائية
EP3593802A3 (en)	2010-05-26	2020-03-25	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
ES2586931T3 (es)	2010-11-04	2016-10-19	Albireo Ab	Inhibidores de IBAT para el tratamiento de enfermedades hepáticas
US20120114588A1 (en)	2010-11-08	2012-05-10	Albireo Ab	Ibat inhibitors for treatment of metabolic disorders and related conditions
RU2619215C2 (ru)	2010-11-08	2017-05-12	Альбирео Аб	Фармацевтическая комбинация, включающая ibat-ингибитор и связующее желчной кислоты
EP2637667A4 (en)	2010-11-08	2014-06-25	Albireo Ab	IBAT HEMMER FOR THE TREATMENT OF METABOLISM DISEASES AND RELATED ACCIDENTS
KR102051031B1 (ko)	2011-10-28	2019-12-02	루메나 파마수티컬즈, 인코포레이티드	고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
BR112014010223B8 (pt)	2011-10-28	2021-02-23	Lumena Pharmaceuticals Llc	uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
JO3301B1 (ar) *	2013-04-26	2018-09-16	Albireo Ab	تعديلات بلورية على إيلوبيكسيبات

2014
- 2014-04-24 JO JOP/2014/0150A patent/JO3301B1/ar active
- 2014-04-25 AU AU2014259433A patent/AU2014259433B2/en active Active
- 2014-04-25 KR KR1020217038464A patent/KR20210148400A/ko not_active Ceased
- 2014-04-25 RU RU2015150039A patent/RU2666368C2/ru active
- 2014-04-25 KR KR1020227037738A patent/KR102683492B1/ko active Active
- 2014-04-25 TW TW103115080A patent/TWI624261B/zh active
- 2014-04-25 SG SG11201507717SA patent/SG11201507717SA/en unknown
- 2014-04-25 DK DK14719331.2T patent/DK2989084T3/en active
- 2014-04-25 CN CN201480022846.3A patent/CN105143194B/zh active Active
- 2014-04-25 UA UAA201511561A patent/UA118847C2/uk unknown
- 2014-04-25 NZ NZ713281A patent/NZ713281A/en unknown
- 2014-04-25 MX MX2015014788A patent/MX370299B/es active IP Right Grant
- 2014-04-25 PL PL14719331T patent/PL2989084T3/pl unknown
- 2014-04-25 CA CA2907842A patent/CA2907842C/en active Active
- 2014-04-25 KR KR1020157030798A patent/KR102445601B1/ko active Active
- 2014-04-25 EP EP14719331.2A patent/EP2989084B1/en active Active
- 2014-04-25 AR ARP140101740A patent/AR096115A1/es unknown
- 2014-04-25 CN CN201810994968.9A patent/CN109096223B/zh active Active
- 2014-04-25 MY MYPI2015703703A patent/MY176157A/en unknown
- 2014-04-25 ES ES14719331.2T patent/ES2622181T3/es active Active
- 2014-04-25 BR BR112015026711A patent/BR112015026711A2/pt not_active Application Discontinuation
- 2014-04-25 PT PT147193312T patent/PT2989084T/pt unknown
- 2014-04-25 WO PCT/EP2014/058432 patent/WO2014174066A1/en not_active Ceased
- 2014-04-25 JP JP2016509484A patent/JP6456921B2/ja active Active
2015
- 2015-09-21 IL IL241766A patent/IL241766B/en active IP Right Grant
- 2015-09-25 ZA ZA2015/07110A patent/ZA201507110B/en unknown
- 2015-09-27 SA SA515361232A patent/SA515361232B1/ar unknown
- 2015-10-06 PH PH12015502309A patent/PH12015502309B1/en unknown
- 2015-10-22 US US14/920,080 patent/US9409875B2/en active Active
- 2015-10-22 CL CL2015003117A patent/CL2015003117A1/es unknown
2016
- 2016-04-21 US US15/134,583 patent/US9701649B2/en active Active
- 2016-04-21 US US15/134,586 patent/US9745276B2/en active Active
2019
- 2019-08-13 PH PH12019501874A patent/PH12019501874B1/en unknown

Also Published As

Publication number	Publication date
AU2014259433A1 (en)	2015-10-15
RU2666368C2 (ru)	2018-09-07
US9745276B2 (en)	2017-08-29
US20160237049A1 (en)	2016-08-18
US9409875B2 (en)	2016-08-09
TWI624261B (zh)	2018-05-21
US9701649B2 (en)	2017-07-11
KR20210148400A (ko)	2021-12-07
RU2015150039A (ru)	2017-05-31
CL2015003117A1 (es)	2016-08-05
SG11201507717SA (en)	2015-10-29
KR20160002842A (ko)	2016-01-08
MX370299B (es)	2019-12-09
JO3301B1 (ar)	2018-09-16
BR112015026711A2 (pt)	2017-07-25
PH12019501874A1 (en)	2020-03-02
CN109096223B (zh)	2022-06-24
CN105143194A (zh)	2015-12-09
UA118847C2 (uk)	2019-03-25
PL2989084T3 (pl)	2017-07-31
HK1221224A1 (en)	2017-05-26
CA2907842A1 (en)	2014-10-30
SA515361232B1 (ar)	2017-09-05
US20160229822A1 (en)	2016-08-11
PH12019501874B1 (en)	2020-03-02
NZ713281A (en)	2020-07-31
KR20220150434A (ko)	2022-11-10
AU2014259433B2 (en)	2018-07-05
EP2989084B1 (en)	2017-01-25
CN105143194B (zh)	2018-10-19
ES2622181T3 (es)	2017-07-05
US20160039777A1 (en)	2016-02-11
JP2016522181A (ja)	2016-07-28
EP2989084A1 (en)	2016-03-02
PH12015502309A1 (en)	2016-02-10
MX2015014788A (es)	2016-03-07
PH12015502309B1 (en)	2016-02-10
CN109096223A (zh)	2018-12-28
RU2015150039A3 (pt)	2018-04-02
KR102683492B1 (ko)	2024-07-09
WO2014174066A1 (en)	2014-10-30
KR102445601B1 (ko)	2022-09-20
CA2907842C (en)	2022-08-23
AR096115A1 (es)	2015-12-09
IL241766B (en)	2019-09-26
TW201521730A (zh)	2015-06-16
DK2989084T3 (en)	2017-05-01
JP6456921B2 (ja)	2019-01-23
MY176157A (en)	2020-07-24
ZA201507110B (en)	2017-09-27

Publication	Publication Date	Title
IL287516A (en)	2021-12-01	Medicinal uses of empagliflozin
ZA201507110B (en)	2017-09-27	Crystal modifications of elobixibat
AU353440S (en)	2014-01-23	Watch
IL241101B (en)	2020-10-29	Medicinal uses of empagliflozin
GB201421334D0 (en)	2015-01-14	Synthesis of aeizeolite
IL241102A0 (en)	2015-11-30	Medicinal uses of empagliflozin
AU355563S (en)	2014-05-16	Wristwatch
LT2981271T (lt)	2019-01-10	Empagliflozino terapinis panaudojimas
AU351857S (en)	2013-11-04	Watch
ZA201604502B (en)	2019-07-31	Use of benzimidazole-proline derivatives
AU350513S (en)	2013-09-02	Wristwatch
GB2509800B8 (en)	2025-07-02	Splint
TWM475821U (en)	2014-04-11	Structure of mosquito-catch
GB2509801B (en)	2016-02-17	Splint
GB201404510D0 (en)	2014-04-30	Crystal structure
AU5220P (en)	2016-06-02	Jewel of DesertTopaz Delosperma cooperi
TWM475524U (en)	2014-04-01	Structure of rivet-pulling
GB201304608D0 (en)	2013-05-01	BenTime of Yisrael operable arrangement
AU352813S (en)	2013-12-09	Wristwatch
GB201310661D0 (en)	2013-10-30	Splint
GB201319828D0 (en)	2013-12-25	Novel use